Loading...
•
Jun 30, 2024
Scholar Rock Q2 2024 Earnings Report
Scholar Rock reported financial results and corporate updates
Key Takeaways
Scholar Rock reported a net loss of $58.5 million for the second quarter of 2024. The company is progressing with its clinical trials, including the Phase 3 SAPPHIRE trial for apitegromab in SMA, and the Phase 2 EMBRAZE trial for apitegromab in obesity.
Remains on track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy (SMA) in 4Q 2024
New data from Phase 2 TOPAZ extension study in patients with nonambulatory SMA showed sustained clinical benefit over 48 months, a continued favorable safety profile with no new safety findings; patient retention rate of over 90%
Phase 2 EMBRAZE proof-of-concept trial enrolling ahead of schedule, topline data expected in 2Q 2025
Presented new SRK-439 preclinical data at American Diabetes Association’s 84th Scientific Sessions (ADA) supporting the potential to contribute to a favorable body composition; increased lean mass and reduced fat mass regain following withdrawal from GLP-1 receptor agonist treatment
Forward Guidance
Scholar Rock is advancing towards multiple milestones and its potential evolution into a commercial-stage company.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...